1-丁氧基-3-甲基丁烷 | 17071-52-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-丁氧基-3-甲基丁烷
• 英文名称: 1-butoxy-3-methylbutane
• 英文别名: butyl-isopentyl ether；n-Butyl-isoamyl-aether；Butyl-isopentyl-aether
• CAS: 17071-52-2
• 化学式: C₉H₂₀O
• 分子量: 144.257
• InChiKey: NMLLTHLOSVNFMY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  10
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-butoxy-3-methyl-buta-1,3-diene 在 Lindlar's catalyst 氢气 作用下， 生成 1-丁氧基-3-甲基丁烷
  参考文献：
  名称：

  Makin,S.M. et al., Journal of general chemistry of the USSR, 1962, vol. 32, p. 1088 - 1092

  摘要：

  DOI：

文献信息

• Predictive and correlative techniques for the design, optimisation and manufacture of solid dosage forms
  作者：Ian J Hardy、Walter G Cook

  DOI：10.1111/j.2042-7158.2003.tb02428.x

  日期：2010.2.18

  There is much interest in predicting the properties of pharmaceutical dosage forms from the properties of the raw materials they contain. Achieving this with reasonable accuracy would aid the faster development and manufacture of dosage forms. A variety of approaches to prediction or correlation of properties are reviewed. These approaches have variable accuracy, with no single technique yet able to provide an accurate prediction of the overall properties of the dosage form. However, there have been some successes in predicting trends within a formulation series based on the physicochemical and mechanical properties of raw materials, predicting process scale-up through mechanical characterisation of materials and predicting product characteristics by process monitoring. Advances in information technology have increased predictive capability and accuracy by facilitating the analysis of complex multivariate data, mapping formulation characteristics and capturing past knowledge and experience.

  目前对从药物剂型所含原材料的性质预测药物剂型性质的兴趣很大。以合理的准确性实现这一点将有助于更快地开发和制造药物剂型。回顾了各种预测或相关性的方法。这些方法的准确性各不相同，目前还没有一种技术能够准确预测药物剂型的整体性质。然而，基于原材料的理化和机械性质预测配方系列内趋势、通过材料的机械特性预测工艺放大以及通过工艺监控预测产品特性等方面已经取得了一些成功。信息技术的进步通过促进对复杂多变量数据的分析、映射配方特性以及捕获过去的知识和经验，提高了预测能力和准确性。

• Continuous-Flow Reductive Alkylation: Synthesis of Bio-based Symmetrical and Disymmetrical Ethers
  作者：Christophe Len、Sophie Bruniaux、Denis Luart

  DOI：10.1055/s-0036-1591861

  日期：2018.5

  materials). For the first time, a reductive alkylation process in continuous flow has been elaborated for the conversion of bio-based alcohols and aldehydes into symmetrical and dissymmetrical high-value-added ethers for industrial companies. The developed method is an etherification associating liquid, solid and gas phases under green conditions (continuous flow, catalysis, bio-based starting materials)

  摘要 对于工业公司来说，首次详细阐述了连续流中的还原性烷基化工艺，用于将生物基醇和醛转化为对称和不对称的高附加值醚。开发的方法是在绿色条件下（连续流动，催化，基于生物的原料）将液相，固相和气相进行醚化反应。 对于工业公司来说，首次详细阐述了连续流中的还原性烷基化工艺，用于将生物基醇和醛转化为对称和不对称的高附加值醚。开发的方法是在绿色条件下（连续流动，催化，基于生物的原料）将液相，固相和气相进行醚化反应。
• Nucleotide and oligonucleotide prodrugs
  申请人：Iyer P. Radhakrishnan

  公开号：US20070149462A1

  公开（公告）日：2007-06-28

  The present invention discloses compounds of formula (I): which exhibit antiviral properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of anti-HBV treatment. The invention also relates to methods of treating a HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明揭示了具有以下式（I）的化合物：这些化合物具有抗病毒性能。本发明还涉及包含上述化合物的药物组合物，用于给需要抗乙型肝炎治疗的受试者使用。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HBV感染的方法。
• THERAPEUTIC COMPOUNDS
  申请人：Old David W.

  公开号：US20080015231A1

  公开（公告）日：2008-01-17

  A compound having a formula is disclosed herein. Therapeutic methods, compositions, and medicaments related thereto are also disclosed.

  本文披露了一种具有化学式的化合物。还披露了与之相关的治疗方法、组合物和药物。
• COMPOUNDS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM
  申请人：Takayama Masami

  公开号：US20090318513A1

  公开（公告）日：2009-12-24

  A compound represented by the general formula (I): wherein R 1 is a hydrogen atom, a halogen atom, or the like; R 2 , R 3 , and R 4 are each independently a hydrogen atom, a halogen atom, C1-C15 alkyl optionally substituted with one or more C1-C12 alkyloxy or the like, or the like; R 5 is a hydrogen atom or the like; R 6 and R 7 are a hydrogen atom or the like; R 8 is C1-C3 alkyl or the like; R 9 is a hydrogen atom or the like), a prodrug, a pharmaceutically acceptable salt, or solvate thereof.

  一种由通式（I）表示的化合物：其中R1是氢原子、卤素原子或类似物；R2、R3和R4各自独立地是氢原子、卤素原子、C1-C15烷基（可选地用一个或多个C1-C12烷氧基或类似物取代）或类似物；R5是氢原子或类似物；R6和R7是氢原子或类似物；R8是C1-C3烷基或类似物；R9是氢原子或类似物。该化合物为一种前药、药物可接受的盐或其溶剂。